United Therapeutics (NASDAQ:UTHR) Releases Quarterly Earnings Results, Misses Estimates By $1.18 EPS

United Therapeutics (NASDAQ:UTHR) announced its quarterly earnings data on Wednesday. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18), FiscalAI reports. The company had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the business earned $6.63 earnings per share.

Here are the key takeaways from United Therapeutics’ conference call:

• United reported ADVANCE OUTCOMES showing ralinepag produced a threefold reduction in PAH disease progression versus background therapy (durable through four years); the company expects FDA review/launch next year and projects ralinepag could materially expand the PAH patient base and drive multi‑billion dollar revenue.
• TETON‑1 and TETON‑2 toplines showed nebulized TYVASO meaningfully improved FVC (over 100 mL) in IPF; United plans a supplemental NDA by end of summer, is pursuing priority review, and targets a potential Q2 next‑year launch if on a standard timeline.
• United disclosed Raldpy, an inhaled DPI form of ralinepag developed with MannKind, completed formulation work and positive pre‑IND interactions, and expects a Phase I IND/healthy‑volunteer study to be completed by year‑end, adding another high‑growth inhaled asset to its pipeline.
• Q1 2026 revenue was $782 million (TYVASO $458M); seasonal weather and pharmacy operational issues slowed patient starts in February but have been addressed, and the company expects sequential growth and a $3→$4B run rate by end‑2027 with further upside from ralinepag and IPF indications.
• Management reiterated a “multiple shots on goal” commercial and development strategy—pursuing oral, DPI, nebulized and SMI formulations (including treprostinil SMI for PH‑COPD), engaging FDA on bridging studies for device/formulation switches, and planning indication‑specific trials.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $569.18 on Friday. The company’s fifty day moving average price is $550.17 and its 200-day moving average price is $501.37. United Therapeutics has a 1-year low of $272.12 and a 1-year high of $609.35. The firm has a market capitalization of $24.05 billion, a P/E ratio of 21.01, a PEG ratio of 1.70 and a beta of 0.60.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of recent analyst reports. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday. Morgan Stanley set a $516.00 target price on United Therapeutics in a research report on Thursday. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Finally, UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 485,155 shares of company stock valued at $266,370,949 over the last 90 days. 10.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of UTHR. Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Rakuten Securities Inc. lifted its stake in shares of United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Geneos Wealth Management Inc. boosted its holdings in United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after buying an additional 85 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its holdings in United Therapeutics by 100.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 168 shares of the biotechnology company’s stock worth $82,000 after buying an additional 84 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.